Linked Life Data

16506951

Source:http://linkedlifedata.com/resource/pubmed/id/16506951

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-3-1
pubmed:abstractText
HIV poses a serious health threat in the world. Mucosal transmission of HIV through the genitourinary tract may be the most important route of transmission. Intranasal immunisations induce vaginal and systemic immune responses. Various protein-, DNA- and RNA-based immunopotentiating adjuvants/delivery systems and live bacterial and viral vectors are available for intranasal immunisations, and these systems may differ in their ability to induce a specific type of immune response (e.g., a cytotoxic T cell versus an antibody response). As the protection against HIV may require both cytotoxic T cell and antibodies, a combination of adjuvants/delivery systems for combinations of mucosal and parenteral immunisations may be required in order to develop a protective anti-HIV vaccine.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1742-5247
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
247-59
pubmed:dateRevised
2009-11-17
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Intranasal delivery of vaccines against HIV.
pubmed:affiliation
Chiron Vaccines, 4560 Horton Street, Emeryville, CA 94608, USA. michael_vajdy@chiron.com
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural